Schonfeld Strategic Advisors
ONCE

Schonfeld Strategic Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,900
Closed -$558K – 1376
2019
Q1 		$558K Buy
+4,900
New +$360K 0.02% 663
2017
Q4 		– Sell
-16,707
Closed -$1.49M – 954
2017
Q3 		$1.49M Buy
16,707
+10,479
+168% +$796K 0.14% 192
2017
Q2 		$372K Sell
6,228
-11,784
-65% -$659K 0.04% 441
2017
Q1 		$961K Buy
+18,012
New +$1.07M 0.1% 261

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Schonfeld Strategic Advisors's ONCE Position: Q2 2019 in Review

Schonfeld Strategic Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2019, closing a stake of 4,900 shares — an estimated $558K sold.

Schonfeld Strategic Advisors first reported a position in ONCE in Q1 2017 and held it in 4 quarters. The position peaked at $1.49M in Q3 2017. 194 funds tracked by Wall St. Rank hold ONCE as of Q2 2019.

  • Schonfeld Strategic Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 4,900 Spark Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $558K.
  • Schonfeld Strategic Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $1.49M in Q3 2017.
  • 194 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.